These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36978140)

  • 1. HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma.
    Li Z; Zhou H; Xia Z; Xia T; Du G; Franziska SD; Li X; Zhai X; Jin B
    Biomark Res; 2023 Mar; 11(1):33. PubMed ID: 36978140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
    Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
    J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.
    Song X; Xu H; Wang P; Wang J; Affo S; Wang H; Xu M; Liang B; Che L; Qiu W; Schwabe RF; Chang TT; Vogl M; Pes GM; Ribback S; Evert M; Chen X; Calvisi DF
    J Hepatol; 2021 Oct; 75(4):888-899. PubMed ID: 34052254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FUT8 is regulated by miR-122-5p and promotes malignancies in intrahepatic cholangiocarcinoma via PI3K/AKT signaling.
    Chen F; Li Y; Aye L; Wu Y; Dong L; Yang Z; Gao Q; Zhang S
    Cell Oncol (Dordr); 2023 Feb; 46(1):79-91. PubMed ID: 36348252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hesperidin delays cell cycle progression into the G0/G1 phase via suspension of MAPK signaling pathway in intrahepatic cholangiocarcinoma.
    Deng J; Liu L; Li L; Sun J; Yan F
    J Biochem Mol Toxicol; 2022 Apr; 36(4):e22981. PubMed ID: 34984768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma.
    Song X; Liu X; Wang H; Wang J; Qiao Y; Cigliano A; Utpatel K; Ribback S; Pilo MG; Serra M; Gordan JD; Che L; Zhang S; Cossu A; Porcu A; Pascale RM; Dombrowski F; Hu H; Calvisi DF; Evert M; Chen X
    Clin Cancer Res; 2019 Jan; 25(1):403-413. PubMed ID: 30084835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma.
    Miao X; Liu C; Jiang Y; Wang Y; Kong D; Wu Z; Wang X; Tian R; Yu X; Zhu X; Gong W
    Cell Death Dis; 2021 Oct; 12(11):1020. PubMed ID: 34716294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MLN2238 exerts its anti-tumor effects
    Xu H; Xu G; Xu Q; Xu C; Zhou X; Bai Y; Yin L; Ding Y; Wang W
    Front Pharmacol; 2022; 13():1040847. PubMed ID: 36386204
    [No Abstract]   [Full Text] [Related]  

  • 9. Correction: HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma.
    Li Z; Zhou H; Xia Z; Xia T; Du G; Franziska SD; Li X; Zhai X; Jin B
    Biomark Res; 2024 Feb; 12(1):27. PubMed ID: 38365852
    [No Abstract]   [Full Text] [Related]  

  • 10. EIF3H stabilizes CCND1 to promotes intrahepatic cholangiocarcinoma progression via Wnt/β-catenin signaling.
    Wei Y; Chen W; Li Z; Xie K; Liu F
    FASEB J; 2022 Dec; 36(12):e22647. PubMed ID: 36350008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.
    Bonelli M; Terenziani R; Zoppi S; Fumarola C; La Monica S; Cretella D; Alfieri R; Cavazzoni A; Digiacomo G; Galetti M; Petronini PG
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708306
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity.
    Asby DJ; Killick-Cole CL; Boulter LJ; Singleton WG; Asby CA; Wyatt MJ; Barua NU; Bienemann AS; Gill SS
    Cancer Manag Res; 2018; 10():3483-3500. PubMed ID: 30254491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMGA1-TRIP13 axis promotes stemness and epithelial mesenchymal transition of perihilar cholangiocarcinoma in a positive feedback loop dependent on c-Myc.
    Li Z; Liu J; Chen T; Sun R; Liu Z; Qiu B; Xu Y; Zhang Z
    J Exp Clin Cancer Res; 2021 Mar; 40(1):86. PubMed ID: 33648560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma.
    Liao W; Du J; Li L; Wu X; Chen X; Feng Q; Xu L; Chen X; Liao M; Huang J; Yuan K; Zeng Y
    J Exp Clin Cancer Res; 2023 May; 42(1):125. PubMed ID: 37198696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
    Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
    Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
    [No Abstract]   [Full Text] [Related]  

  • 16. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
    Yamamoto T; Kanaya N; Somlo G; Chen S
    Breast Cancer Res Treat; 2019 Apr; 174(3):615-625. PubMed ID: 30607633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysregulation of the miR-148a-GLUT1 axis promotes the progression and chemoresistance of human intrahepatic cholangiocarcinoma.
    Tiemin P; Peng X; Qingfu L; Yan W; Junlin X; Zhefeng H; Ming Z; Desen L; Qinghui M
    Oncogenesis; 2020 Feb; 9(2):19. PubMed ID: 32054829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors.
    Cai Z; Wang J; Li Y; Shi Q; Jin L; Li S; Zhu M; Wang Q; Wong LL; Yang W; Lai H; Gong C; Yao Y; Liu Y; Zhang J; Yao H; Liu Q
    Sci China Life Sci; 2023 Jan; 66(1):94-109. PubMed ID: 35982377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
    Gul A; Leyland-Jones B; Dey N; De P
    Am J Cancer Res; 2018; 8(12):2359-2376. PubMed ID: 30662797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma.
    Peng M; Li H; Cao H; Huang Y; Yu W; Shen C; Gu J
    J Gastroenterol; 2023 Sep; 58(9):908-924. PubMed ID: 37433897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.